Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

cAMPfield Therapeutics raises $180M in a Series A funding round, led by Frazier Life Sciences, to advance their oral drug for inflammatory bowel diseases.

PRIVATEJun 18, 2026•about 2 months ago

Amount Raised

$180 Million

Round Type

Series A

San DiegoBiotechnologyHealth Care

Investors

Ra CapitalNovo HoldingsLongitude CapitalVenrockAbingworthForbionDeep Track CapitalFrazier Life Sciences

Description

cAMPfield Therapeutics has secured $180 million in a Series A funding round to support the development of its oral drug for inflammatory bowel diseases. The company, founded with a focus on innovative therapies for inflammatory conditions, is based in San Diego. This financing was led by Frazier Life Sciences, with participation from several prominent investors. The funds will be used to launch global phase 2b trials for ulcerative colitis and phase 2 trials for Crohn’s disease.

Company Information

Company

cAMPfield Therapeutics

Location

San Diego, California, United States

About

cAMPfield Therapeutics is a biotech company focused on developing oral medicines for inflammatory bowel diseases (IBD). Recently launched with a $180 million series A funding round, the company is advancing its lead candidate, prifemilast, through global clinical trials. The company aims to establish a new standard of care in treating IBD by leveraging selective PDE4 inhibition. Founded by industry veterans and backed by prominent investors, cAMPfield represents a new model in biotech originating from China.

Related People

Suggested for you
1 contact
Verified contactsPatricia T., Chief Technical Officer hidden
Predictive Intelligence
Strategic

ML-powered predictions for cAMPfield Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.